Gallbladder cancer

The gallbladder stores bile made by the liver. Cancer can begin in its lining and grow through its wall into nearby structures. It may be discovered unexpectedly when the removed gallbladder is examined after surgery for stones or inflammation. An incidental finding is a way the cancer was detected, not a separate stage.

Pain, nausea, jaundice, appetite loss or fever can also come from benign gallbladder disease. Gallstones are a risk factor, but most people with stones never develop this cancer. New persistent symptoms deserve assessment without assuming that stones or pain mean cancer.

Most gallbladder cancers are adenocarcinomas. Unusual histologies, such as a high-grade neuroendocrine carcinoma, need a different treatment discussion. Request the complete report rather than only the word ‘malignant’. Depth, grade, margins, vascular or nerve invasion and any sampled lymph nodes help define risk.

AJCC’s current site-specific listing retains the eighth-edition gallbladder system. The T category describes local invasion; nodes and distant spread are separate. T1a and T1b are therefore not interchangeable, even though both begin with ‘T1’.

For a completely removed T1a cancer with clear margins, simple cholecystectomy is generally adequate. T1b disease reaches the muscle; patients with incidental T1b, T2 or selected T3 disease should have specialist assessment for completion resection if staging and fitness allow. The decision is based on the full specimen and imaging, not on whether the first surgeon saw a mass.

Completion surgery can involve adjacent liver tissue and regional lymph nodes. More extensive liver or bile duct removal is not automatically better; the goal is a clear margin with acceptable risk. Bring the original operation report, including perforation or bile spillage, specimen handling and any concerns about the cystic duct margin.

Contrast imaging evaluates the gallbladder bed, liver, bile ducts, blood vessels, abdominal nodes and distant sites. MRI can clarify liver or biliary findings. Selected patients have staging laparoscopy to look for spread not apparent on scans before a major operation. Biopsy planning depends on whether surgery or systemic therapy is being considered.

Direct growth into the liver beside the gallbladder differs from a separate distant liver metastasis. Jaundice may reflect obstruction and does not establish the stage by itself. Resectability also depends on whether the disease can be removed safely and whether the patient can recover from the necessary operation.

Recovery and final pathology guide the adjuvant discussion. Capecitabine is an established option after resection of biliary tract cancer, including appropriate gallbladder cancer cases. A very superficial tumor adequately removed at the first operation should not automatically be treated like node-positive invasive disease.

An involved margin or other high-risk findings may lead to discussion of radiation or chemoradiation in selected cases. The team should explain the expected benefit, uncertainty and effects on recovery. Follow-up remains necessary after surgery; the schedule is tailored to recurrence risk, symptoms and treatment received.

Gemcitabine and cisplatin with durvalumab or pembrolizumab are first-line options for suitable patients with advanced biliary tract cancer, including gallbladder cancer. These US chemotherapy–immunotherapy indications do not require PD-L1 positivity. Kidney function, hearing, infection, existing neuropathy and daily functioning influence whether the full combination is appropriate.

After progression, FOLFOX is one evidence-based chemotherapy option for patients fit for further treatment. Molecular results, prior adverse effects and clinical trials may offer other paths. The supporting biliary trials include several primary sites, so a result for the whole trial should not be presented as a guaranteed gallbladder-specific benefit for an individual.

Plan molecular profiling early in advanced disease. HER2 protein expression and gene amplification are particularly relevant in gallbladder cancer, but are not the same test. MSI/MMR and broader profiling may identify additional options. A result must be matched to the exact medicine and indication; FGFR2 or IDH1 approvals specifically for cholangiocarcinoma should not simply be relabeled as gallbladder approvals.

In the US, zanidatamab monotherapy has accelerated approval for previously treated adults with unresectable or metastatic HER2 IHC 3+ biliary tract cancer. Trastuzumab deruxtecan has a separate accelerated indication for previously treated unresectable or metastatic IHC 3+ solid tumors without satisfactory alternatives. HER2 mutation alone or IHC 2+ alone does not meet these IHC 3+ definitions.

MSI-high or mismatch-repair-deficient disease can support a separate biomarker-directed immunotherapy discussion under the relevant treatment conditions. If an immune checkpoint inhibitor was already part of first-line therapy, giving another one after progression is not automatically an effective strategy. Targeted treatment and trial access still require a case-specific review.

Bile duct obstruction, infection and poor intake can interfere with cancer treatment and need active management. Fever or chills with jaundice, confusion or severe weakness require urgent assessment. Persistent vomiting, inability to drink or rapidly worsening pain should also be reported promptly.

After gallbladder surgery, discuss persistent diarrhea, appetite loss or weight change rather than imposing a restrictive diet without assessment. Treatment follow-up also includes liver and kidney tests and medicine-specific monitoring. New cough or breathlessness during trastuzumab deruxtecan treatment needs prompt attention because of possible lung inflammation.

• Full pathology, including depth, cystic duct margin and lymph node findings.
• Original cholecystectomy report and all staging scans.
• Molecular results, treatment history and current drainage or nutritional problems.